Analysts think NCNA stock price could increase by 1707%
Nov 22, 2024, 12:25 PM
-4.72%
What does NCNA do
NuCana PLC is a UK-based biopharmaceutical company focused on cancer treatments using ProTide technology, with candidates NUC-3373 and NUC-7738 currently in Phase I/II clinical trials. The company's pipeline also includes Acelari, a ProTide transformation of gemcitabine.
4 analysts think NCNA stock price will increase by 1707.09%. The current median analyst target is $22.95 compared to a current stock price of $1.27. The lowest analysts target is $20.20 and the highest analyst target is $26.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
